Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of HSK31679 in Healthy and Elevated LDL-C Subjects
NCT05531097Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing HSK31679 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events, Clinical Laboratory Parameters and 2 more. Started Feb 2022; status: completed.
02
Drugs
HSK31679
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05531097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531097.